Physician profile
Stuart Okin
NPI 1770563538
$7,675.24
in general payments reported to CMS, 2019-2025
29 companies · $853 in 2025
The $853 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $1,203 · 2021: $1,564 · 2022: $1,087 · 2023: $979 · 2024: $1,040 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,872.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,114.80 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $850.05 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $848.52 | 2019-2025 | Jardiance |
| Amgen INC. | $843.71 | 2019-2025 | Repatha, Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $514.41 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $495.25 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $438.33 | 2019-2024 | Xarelto |
| Edwards Lifesciences Corporation | $375.39 | 2020-2025 | Sapien 3 Ultra Resilia |
| Esperion Therapeutics, INC. | $369.03 | 2020-2025 | Nexletol |
| Abbvie INC. | $305.53 | 2021-2022 | |
| Allergan, INC. | $215.20 | 2019-2020 | |
| Amarin Pharma, INC. | $192.55 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $179.37 | 2020-2024 | Farxiga |
| Lilly USA, LLC | $152.28 | 2022-2024 | Mounjaro, Zepbound |
| Heartflow, INC. | $102.69 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $99.23 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $78.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $73.07 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $72.70 | 2019-2021 | |
| Novo Nordisk INC | $71.84 | 2019-2023 | Wegovy, Saxenda |
| Abbott Laboratories | $65.36 | 2022-2025 | Gallant, Mitraclip |
| Alnylam Pharmaceuticals INC. | $48.96 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $36.82 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $24.80 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $22.69 | 2020 | |
| Hikma Pharmaceuticals USA | $22.58 | 2020 | |
| Phadia US INC. | $20.96 | 2025 | Immunocap |
| Irhythm Technologies, INC. | $20.15 | 2022 | |
| Bardy Diagnostics, INC. | $20.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Okin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.